有人 Lv12 关闭了本次求助。

说明 求助违规（查看求助规则）：该文献不存在全文(会议摘要、视频、poster、research highlight、news等)【积分已退回】

201314zlj君 求助人 Lv1 进行了留言

2023 AACR正文求助 First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations

回复

201314zlj君 求助人 Lv1 发起了本次求助